Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

Kenvue Inc. Common Stock (NY:KVUE)

23.73 +0.23 (+0.98%)
Official Closing Price Updated: 7:00 PM EDT, May 23, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Kenvue Inc. Common Stock

< Previous 1 2
...
12 13 14 15 16 17 18 19 Next >
Benzinga's Top Ratings Upgrades, Downgrades For June 1, 2023
Via Benzinga
Kenvue to Participate in the Deutsche Bank dbAccess Global Consumer Conference on June 8, 2023
From Kenvue Inc.
Via Business Wire
Kenvue Stock Up 5.37% Since IPO
Via Benzinga
Kenvue's Growth Forecast: Exploring The Future Of Johnson & Johnson's Carve-Out
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For May 30, 2023
Via Benzinga
7 Consumer Stocks to Buy and Hold for the Long Haul
For steady dividends and price appreciation, consider adding these seven best long-term consumer stocks to your portfolio. 
Via InvestorPlace
3 Dow Stocks Poised for a Roaring Relief Rally
Here are some compelling Dow stocks to buy if you believe the market may be on the cusp of a relief rally this summer. 
Via InvestorPlace
Got $1,000? 5 Buffett Stocks to Buy and Hold Forever
Warren Buffett owns many stocks, but these five have solid growth potential. 
Via The Motley Fool
Kenvue Just IPO'd, but Is the Stock a Buy?
The Johnson & Johnson spinoff is worth considering, but it's not a must-buy. 
Via The Motley Fool
2 Dividend Stocks to Double Up On Right Now
These dividend stocks look attractive right now. 
Via The Motley Fool
Kenvue Has Gone Public: Should You Buy the Stock?
Its business could be resistant to the effects of inflation. 
Via The Motley Fool
Which Is the Better Forever Stock: Johnson & Johnson or UnitedHealth Group?
Both stocks have built-in economic diversity and are solid long-term investments. 
Via The Motley Fool
2 No-Brainer Healthcare Stocks to Buy Right Now
Boring businesses can make for beautiful lifelong holdings -- these two stocks show us why. 
Via The Motley Fool
How Apple Pleased Investors
We've got a lot of ground to cover as company earnings reports continue to flood in. 
Via The Motley Fool
7 Overvalued Stocks to Sell for May 2023
It's easy to fall into the trap of getting overvalued stocks. What may have been a great buy a year ago could be overvalued today. 
Via InvestorPlace
2 Warren Buffett Stocks to Buy Hand Over Fist in May
These two Berkshire Hathaway holdings are solid picks in May. 
Via The Motley Fool
J&J Kenvue Spinoff Aims To Give Investors A Healthy Return
Johnson & Johnson spinoff Kenvue had the biggest IPO since 2021, raising $3.8 billion. Kenvue's brands include Band-Aid, Tylenol, Neutrogena and Listerine. 
Via MarketBeat
Topics Initial Public Offering
Exposures Securities Market
Kenvue Announces Closing of Initial Public Offering
From Kenvue Inc.
Via Business Wire
Does Johnson & Johnson's Kenvue Spinoff Make Sense?
We also look at Darden Restaurants' acquisition and Yum! Brands' quarter. 
Via The Motley Fool
These 2 Top Stocks Just Declared Dividend Raises
These companies manage to keep growing and generating excess profits, which is admirable given their age and size. 
Via The Motley Fool
J&J's Kenvue Jumps 20% In Market Debut
Shares of Johnson & Johnson's consumer-health spin-off Kenvue soared 20% in their market debut on Thursday, making it the biggest U.S. IPO in over a year. Under Kenvue's umbrella are widely-known... 
Via Talk Markets
3 Great Income Stocks That Retirees Should Love
If you're looking for additional retirement income, these three stocks should be right up your alley. 
Via The Motley Fool
S&P 500 Finishes Strong Following Wild Week Of Bank Stock Volatility
The Fed's tenth consecutive interest rate hike, the buyout of First Republic's assets by JPMorgan Chase & Co (NYSE: JPM) and a hot April jobs report gave investors plenty to digest this week. 
Via Benzinga
Acelyrin Raises $540M In IPO, Stock Gains Over 20% In Trading Debut
Acelyrin Inc (NASDAQ: SLRN), a late-stage clinical biopharma company, started trading today and opened at $23/share compared to IPO  
Via Benzinga
Which Healthcare Stock Is a Compelling Pick for the Long Haul?
Healthcare stocks are especially resilient in times of uncertainty. Let's take a look at three compelling picks. 
Via InvestorPlace
SLRN Stock IPO: When Does Acelyrin Go Public? What Is the Acelyrin IPO Price Range?
Here's what prospective investors in Acelyrin and SLRN stock may want to watch out for as the company gears up for its IPO. 
Via InvestorPlace
< Previous 1 2
...
12 13 14 15 16 17 18 19 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.